pemetrexed
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Central Nervous System Lymphoma
Conditions
Central Nervous System Lymphoma
Trial Timeline
Jan 1, 2009 → Sep 1, 2015
NCT ID
NCT00916630About pemetrexed
pemetrexed is a phase 1 stage product being developed by Eli Lilly for Central Nervous System Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00916630. Target conditions include Central Nervous System Lymphoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00035061 | Phase 2 | Completed |
| NCT03955042 | Phase 1 | Completed |
| NCT01473563 | Phase 2 | Completed |
| NCT00916630 | Phase 1 | Completed |
| NCT00732303 | Phase 2 | Terminated |
| NCT00864513 | Phase 2 | Terminated |
| NCT00520936 | Phase 2 | Completed |
| NCT00523419 | Phase 2 | Completed |
| NCT00540241 | Pre-clinical | Completed |
| NCT00497770 | Pre-clinical | Completed |
| NCT00316225 | Phase 2 | Completed |
| NCT00380718 | Approved | Completed |
| NCT00377520 | Phase 2 | Completed |
| NCT00190918 | Phase 2 | Completed |
| NCT00330915 | Phase 2 | Completed |
| NCT00109096 | Phase 2 | Completed |
| NCT00106002 | Phase 2 | Completed |
| NCT00216099 | Phase 2 | Completed |
| NCT00190983 | Phase 2 | Completed |
| NCT00216216 | Phase 2 | Terminated |
Competing Products
20 competing products in Central Nervous System Lymphoma